Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, US Multicenter Open Label Study in the Treatment of Hepatocellular Carcinoma (HCC) With a Radiopaque (RO) Bead (LC Bead LUMI) Loaded With Doxorubicin

Trial Profile

A Prospective, US Multicenter Open Label Study in the Treatment of Hepatocellular Carcinoma (HCC) With a Radiopaque (RO) Bead (LC Bead LUMI) Loaded With Doxorubicin

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 21 Aug 2018

At a glance

  • Drugs Doxorubicin (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors BTG International
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 09 Aug 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 13 Apr 2018 Planned initiation date changed from 1 Apr 2018 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top